Related Experiment Video
Updated: Jan 11, 2026
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
Pulmonary Mucormycosis with Endobronchial Involvement Complicated by Pleural Effusion
Bilal Rabahoğlu1, Nuri Tutar1, Hilal Bozkurt1
1Department of Pulmonary Medicine, Erciyes University Faculty of Medicine, Kayseri, Türkiye.
Background:
Pulmonary mucormycosis is an infection caused by a fungus with a severe and often fatal course, with a mortality rate exceeding 50%. It can spread through blood or lymphatic fluids or by inhalation of sporangiospores. Immunocompromised patients are especially susceptible to this high mortality rate. Histopathology is used to identify nonseptate hyphae in tissue, and culture is used to confirm the diagnosis. Treatment usually involves a combination of aggressive surgery and medication.
Case Report:
A patient with diabetes mellitus received corticosteroid treatment for facial paralysis, which led to the diagnosis of pulmonary mucormycosis. Without requiring surgical resection, the patient was successfully treated with intravenous antifungal medication, along with intrabronchial and intrapleural liposomal amphotericin B.
Conclusion:
Pulmonary mucormycosis requires prompt diagnosis and treatment. Close monitoring of such infections may minimize the need for invasive procedures and lower mortality, particularly when endobronchial involvement accompanied by effusion is present.
Insights
Pulmonary mucormycosis, a severe fungal infection, has a high mortality rate. Early diagnosis and treatment, potentially avoiding surgery, can improve outcomes in susceptible patients.
Area of Science:
- Mycology
- Infectious Diseases
- Pulmonology
Background:
- Pulmonary mucormycosis is a severe fungal infection with over 50% mortality.
- It spreads via inhalation, blood, or lymph, primarily affecting immunocompromised individuals.
- Diagnosis involves histopathology for nonseptate hyphae and culture confirmation.
Related Concept Videos
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
01:30Endoscopic Studies I: Bronchoscopy and Thoracoscopy
Bronchoscopy
Description
Bronchoscopy is a procedure that involves direct visualization of the larynx, trachea, and bronchi for diagnostic and therapeutic purposes. A flexible fiber optic or rigid bronchoscope is used to carry out the procedure. The fiber-optic bronchoscope is more frequently used due...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:30Pneumonia III: Complications and Assessment
01:31Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories: